Rasagiline: a guide to its use in Parkinson's disease.

Abstract

Oral rasagiline (Azilect®) as monotherapy or as an adjunct to levodopa provides a useful option in the symptomatic treatment of adult patients with Parkinson's disease. In patients with early Parkinson's disease, monotherapy with rasagiline 1 mg/day improved symptoms of the disease relative to placebo. As adjunctive therapy to levodopa in patients with advanced Parkinson's disease, rasagiline 0.5 or 1 mg/day significantly reduces the total daily 'off' time. Rasagiline is generally well tolerated when administered as monotherapy or as adjunctive therapy.

• Authors: Gillian M Keating, Katherine A Lyseng-Williamson, Sheridan M Hoy
• Journal: CNS drugs (CNS Drugs) Vol. 26 Issue 9 Pg. 781-5 (Sep 1 2012) ISSN: 1172-7047 [Print] New Zealand
• PMID: 22834567 (Publication Type: Journal Article)

Chemical References

• Antiparkinson Agents
• Indans
• Monoamine Oxidase Inhibitors
• rasagiline
• Levodopa
• Dopamine

Topics

• Administration, Oral
• Antiparkinson Agents (administration & dosage, adverse effects, therapeutic use)
• Dopamine (metabolism)
• Dose-Response Relationship, Drug
• Drug Administration Schedule
• Drug Therapy, Combination
• Humans
• Indans (administration & dosage, adverse effects, therapeutic use)
• Levodopa (administration & dosage, adverse effects, therapeutic use)
• Monoamine Oxidase Inhibitors (administration & dosage, adverse effects, therapeutic use)
• Parkinson Disease (drug therapy, enzymology)
• Practice Guidelines as Topic
• Randomized Controlled Trials as Topic
• Treatment Outcome